Dielsdorf, Switzerland (PRWEB) September 04, 2013
Today, Senn Chemicals announced the appointment of Dr. Thomas Eisele as their new Chief Executive Officer. Dr. Eisele was previously with CarboGen-Amcis, Novasep-Rohner and Synphabase, and most recently at Hovione, where he held the position of Vice President, Corporate R&D.
Interim CEO, Carlo Haechler, will actively guide the transition while remaining as the functional chief executive until 30 September 2013. After which time, Dr. Eisele will take the helm and Mr. Haechler will remain in an advisory role to Senn Chemicals.
“We are delighted to welcome Dr. Eisele to the Senn team,” commented Senn Chairman of the Board, Christoph Schmid. “He provides us with a robust combination of broad scientific acumen and market savvy, which will be essential to our successful expansion plans both in terms of production capacity and global market reach.”
"I am excited and honoured about this new opportunity to lead the Senn Chemicals team in Switzerland. Throughout my career I have had a great respect for Senn, a company that is recognized as a world leader in peptide manufacturing. I am looking forward to helping further enhance Senn´s established reputation for offering tailor made solutions for our partners and to develop a successful company into a premier global player providing integrated solutions for any molecule," said Dr. Eisele.
Dr. Eisele is trained as an organic chemist at the University of Constance, Germany and holds a PhD from the same university. He brings over 16 years of experience in the development and scale-up of APIs from lead candidate optimization through NDA submission and commercialization. Dr. Eisele is intimately familiar with CRO and CMO operations and related quality requirements. Moreover, his business development and broad reaching staff management responsibilities provide him with the ideal experience base to lead the growing company to new levels of success.
ABOUT SENN CHEMICALS
Senn is a contract manufacturing organization specializing in custom synthesis of peptides and related compounds for use as active pharmaceutical ingredients and intermediates. Based in Dielsdorf, Switzerland, Senn has provided full service CMO support for biotechnology and pharmaceutical organizations worldwide since 1963.
Read the full story at http://www.prweb.com/releases/2013/9/prweb11083082.htm.
Copyright©2012 Vocus, Inc.
All rights reserved